Global Cord Blood Corporation and Margot MacInnis, John Royle, and Chow Tsz Nga Geor

CourtUnited States Bankruptcy Court, S.D. New York
DecidedDecember 5, 2022
Docket22-11347
StatusUnknown

This text of Global Cord Blood Corporation and Margot MacInnis, John Royle, and Chow Tsz Nga Geor (Global Cord Blood Corporation and Margot MacInnis, John Royle, and Chow Tsz Nga Geor) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Global Cord Blood Corporation and Margot MacInnis, John Royle, and Chow Tsz Nga Geor, (N.Y. 2022).

Opinion

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK --------------------------------------------------------------- In re: ) ) ) Chapter 15 GLOBAL CORD BLOOD CORPORATION, ) ) Case No. 22-11347 (DSJ) ) Debtor in a Foreign Proceeding. ) ---------------------------------------------------------------

MEMORANDUM OF DECISION AND ORDER DENYING CHAPTER 15 PETITION FOR RECOGNITION OF A FOREIGN PROCEEDING APPEARANCES: MORGAN, LEWIS BOCKIUS LLP Counsel for Joint Provisional Liquidators of Global Cord Blood Corporation 101 Park Avenue New York, NY 10178 By: Joshua Dorchak, Esq. John C. Goodchild, Esq. Matthew C. Ziegler, Esq.

KOBRE & KIM LLP Counsel for Golden Meditech Stem Cells (BVI) Company Limited 800 Third Avenue 6th Floor New York, NY 10022 By: Daniel J. Saval, Esq. John G. Conte, Esq.

WHITE & CASE LLP Counsel for Independent Directors of Global Cord Blood Corporation 111 South Wacker Drive Suite 5100 Chicago, Illinois 60606 By: Bojan Guzina, Esq. DAVID S. JONES UNITED STATES BANKRUPTCY JUDGE This Chapter 15 case arises out of proceedings pending in the Grand Court of the Cayman Islands (“Cayman Proceeding”). In response to evidence suggesting that a company’s board and/or officers caused or allowed an improper expenditure of more than $600 million of corporate funds, the Grand Court appointed Joint Provisional Liquidators (“JPLs”) as fiduciaries to investigate and, if appropriate, seek to recover misappropriated funds, and/or to take other actions as may be appropriate based on the findings of their investigation. The Cayman Grand Court conferred extensive corporate powers on the JPLs and divested the power of a number of the company’s board members.

The JPLs have petitioned this Court for recognition of the Cayman Proceeding under Chapter 15 of the U.S. Bankruptcy Code. This application, which has drawn two objections, tests the limits of how broadly Chapter 15 can be applied to assist a foreign court in its conduct of a case that does not involve insolvency or the identification, classification, or satisfaction of debts. For reasons detailed below, the Court concludes that, on the present record, the Cayman

Proceeding does not satisfy the Bankruptcy Code’s definition of a “foreign proceeding” and, accordingly, is not eligible for recognition under Chapter 15. At bottom, the Court concludes that the Cayman Proceeding, which arises under various subsections of the Cayman Islands Companies Act (“Companies Act”), is most akin to a corporate governance and fraud remediation effort, and is not a collective proceeding for the purpose of dealing with insolvency, reorganization, or liquidation. As such, the Cayman Proceeding at its present stage falls outside the range of proceedings that Chapter 15 was designed to assist. To hold otherwise would be to invite recourse to U.S. bankruptcy courts whenever any foreign corporation sustains losses as a result of officer or director fraud or defalcation, so long as that corporation first commences proceedings in its home jurisdiction seeking to install new fiduciaries and right the wrong that the corporation has suffered. Although Chapter 15 is to be applied broadly to provide assistance to a wide variety of foreign proceedings, the proceeding

here—at its present stage—falls outside the range of types of proceedings that have been found eligible for assistance under Chapter 15, and outside the meaning of applicable provisions of the Bankruptcy Code. The Petition is therefore denied, without prejudice to future applications by the JPLs or other authorized representatives if warranted by future developments in the Cayman Proceeding or elsewhere.

BACKGROUND The Court conducted a hearing on November 10, 2022, and, by agreement of the parties, received in evidence declarations submitted by each side, along with exhibits. No party opted to question any witness despite having been afforded the opportunity to do so.

This factual background section draws on that evidentiary record, which includes substantial portions of the record of the Cayman Proceeding. Neither party questioned the factual accuracy of any of the statements and facts presented about the Cayman Proceeding, although each party contests the inferences and legal significance of those facts and parties opposing recognition dispute the JPLs’ claims of malfeasance. The Court therefore credits the factual content of the parties’ submissions, which form the factual basis of the Court’s ruling. The salient background

is as follows. Three Joint Provisional Liquidators who have been appointed by the Grand Court of the Cayman Islands in a matter relating to Global Cord Blood Corporation (“Global Cord Blood Corp.” or the “Company”) have petitioned this Court for recognition of what they assert is a foreign main proceeding pending in the Grand Court of the Cayman Islands. [ECF Nos. 1, 2]. The JPLs seek recognition of the Cayman Proceeding as a foreign main proceeding or, in the

alternative, as a foreign nonmain proceeding; they also seek related relief including authorization to conduct discovery in the United States in connection with assertedly fraudulent misconduct including what the JPLs assert was a possible misappropriation of more than $600 million in corporate funds. Two groups—a group of now-disempowered former directors of the Company, and another entity with an interest in the company (collectively the “Objectors”)—oppose the application for

recognition. [See ECF Nos. 12, 16]. An “Objection” [ECF No. 12] was filed by Golden Meditech Stem Cells (BVI) Company Limited (“Golden Med”), which asserts that it holds a direct or indirect ownership stake in Global Cord Blood Corp. Individuals who term themselves Independent Directors of Global Cord Blood Corporation filed a “Statement in Support” [ECF No. 16] of Golden Med’s objection. The Objectors argue, in essence, that recognition is inappropriate because the Cayman proceeding is not a “foreign proceeding” as that term is defined in section 101(23) of the Bankruptcy Code, and, accordingly, the proceeding is ineligible for recognition under section 1517 of the Code.

1. Global Cord Blood Corp. Global Cord Blood Corp. is a Cayman Islands exempted company that primarily operated in the People’s Republic of China (“PRC”) with headquarters in Hong Kong. [ECF No. 3 at ¶¶ 9, 12]. The Company’s business deals with collecting and storing umbilical cord blood for its stem cell content. [ECF No. 2 at ¶ 10]. The Company is or was a sizeable concern with shares that traded on the New York Stock Exchange. [See ECF No. 3 at ¶ 10].

Golden Med frames the Cayman Proceeding as the outgrowth of a longstanding struggle for corporate control waged by two shareholders through multiple layers of holding companies. [See ECF. No. 12 at ¶¶ 9–17]. Two entities—Golden Med and Blue Ocean Structure Investment (BVI) Company Limited (“Blue Ocean”)—assert conflicting ownership stakes in Global Cord Blood Corp. [Id. at ¶¶ 9–19]. According to Golden Med, this dispute is the subject of ongoing litigation in the British Virgin Islands. [Id. at ¶¶ 26–28].

Blue Ocean alleges that, in April 2022, Global Cord Blood Corp. entered into a questionable transaction that transferred or purported to transfer millions of new shares of stock and over $600 million in corporate funds to two companies, including one called Cellenkos (the “Cellenkos Transaction”). [See ECF Nos. 3-3 at ¶¶ 17–32, 12 at ¶ 21]. This transaction is the subject of the Cayman Proceeding. [ECF No. 2 at ¶ 12]. 2. The Cayman Proceeding

Blue Ocean, as a significant shareholder of Global Cord Blood Corp., sought relief from the Cellenkos Transaction in the Grand Court of the Cayman Islands by filing a “Winding Up Petition” on May 5, 2022. [ECF No. 3-2]. In its petition, Blue Ocean alleges that some combination of Global Cord Blood Corp.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Morning Mist Holdings Ltd. v. Krys
714 F.3d 127 (Second Circuit, 2013)
In Re Gold & Honey, Ltd.
410 B.R. 357 (E.D. New York, 2009)
In Re Mmg LLC
256 B.R. 544 (S.D. New York, 2000)
In Re Betcorp Ltd.
400 B.R. 266 (D. Nevada, 2009)
In Re British American Ins. Co. Ltd.
425 B.R. 884 (S.D. Florida, 2010)
In Re Netia Holdings S.A.
277 B.R. 571 (S.D. New York, 2002)
King v. Time Warner Cable Inc.
894 F.3d 473 (Second Circuit, 2018)
In re Millard
501 B.R. 644 (S.D. New York, 2013)
In re Rede Energia S.A.
515 B.R. 69 (S.D. New York, 2014)
In re Suntech Power Holdings Co.
520 B.R. 399 (S.D. New York, 2014)
In re OAS S.A.
533 B.R. 83 (S.D. New York, 2015)
In re Creative Finance Ltd.
543 B.R. 498 (S.D. New York, 2016)
In re Ocean Rig UDW Inc.
570 B.R. 687 (S.D. New York, 2017)
In re Poymanov
571 B.R. 24 (S.D. New York, 2017)
In re B.C.I. Finances Pty Ltd.
583 B.R. 288 (S.D. New York, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Global Cord Blood Corporation and Margot MacInnis, John Royle, and Chow Tsz Nga Geor, Counsel Stack Legal Research, https://law.counselstack.com/opinion/global-cord-blood-corporation-and-margot-macinnis-john-royle-and-chow-tsz-nysb-2022.